– Organizational focus on DURAVYU TM Phase 3 DME program; trials fully enrolled with topline data expected in early Q4 2027 – – DURAVYU DME program supported by the positive Phase 2 VERONA trial and multi-MOA activity blocking both VEGF and inflammatory IL-6 pathways involved in disease pathogenesis – – Strategic prioritization expected to generate $30 million in annualized savings – – $118 mil...
WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced a strategic prioritization designed to reduce operating expenses and focus resources on its late-stage program for DURAVYU™ in diabetic macular edema (DME).
– LUCIA did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept control, despite demonstrating visual improvement – – Key secondary endpoints in LUCIA were met including a superior 38% reduction in treatment burden (nominal p-value
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
WATERTOWN, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employee as inducement award outside the Company's 2023 Long-Term Incentive Plan in accordance with N...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.